硼替佐米治疗抗 N-甲基-D-天冬氨酸受体（NMDA-R）脑炎：一项系统评价。
Bortezomib in anti-N-Methyl-d-Aspartate-Receptor (NMDA-R) encephalitis: A systematic review.
机构信息
Neurology Unit, "San Martino" Hospital, AULSS 1 - Dolomiti, Viale Europa, 22, 32100 Belluno, Italy; Clinical Unit of Neurology, Department of Medicine, Surgery and Health Sciences, Cattinara University Hospital ASUGI, University of Trieste, Strada di Fiume, 447, 34149 Trieste, Italy.
Clinical Unit of Neurology, Department of Medicine, Surgery and Health Sciences, Cattinara University Hospital ASUGI, University of Trieste, Strada di Fiume, 447, 34149 Trieste, Italy.
出版信息
J Neuroimmunol. 2021 Jul 15;356:577586. doi: 10.1016/j.jneuroim.2021.577586. Epub 2021 Apr 28.
N-methyl-d-aspartate receptor (NMDAR) encephalitis is a potentially treatable condition, although a small proportion of patients remains refractory to immunotherapy. Bortezomib is a proteasome inhibitor that has a promising role in autoimmune conditions. We performed an independent PubMed search employing "Anti-N-Methyl‑D-Aspartate encephalitis AND bortezomib", including papers published between January 1st, 2007 to April 15th, 2021. Fourteen articles were included, with 29 patients. 16 patients (55,2%) had a favorable outcome after bortezomib and 11 (37,9%) patients developed side effects. Quality of studies was overall poor and future trials should aim to include more homogeneous and larger cohorts.
N-甲基-D-天冬氨酸受体（NMDAR）脑炎是一种有潜在治疗效果的疾病，尽管仍有一小部分患者对抗免疫治疗没有反应。硼替佐米是一种蛋白酶体抑制剂，在自身免疫性疾病中具有广阔的应用前景。我们在 PubMed 上进行了一次独立的检索，检索词为“Anti-N-Methyl-D-Aspartate encephalitis AND bortezomib”，检索时间范围为 2007 年 1 月 1 日至 2021 年 4 月 15 日。共纳入 14 篇文章，共涉及 29 名患者。29 名患者中，16 名（55.2%）在接受硼替佐米治疗后预后良好，11 名（37.9%）出现不良反应。研究的总体质量较差，未来的试验应旨在纳入更同质和更大的队列。
Zotero 插件